Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/23/15Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma
-Second of Two Planned Trials Combining ADCETRIS and Opdivo Under Clinical Collaboration Agreement- BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Dec. 23, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb (NYSE:BMY) today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or ... 
Printer Friendly Version
12/10/15Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium
First Clinical Data Presentation of SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with Triple Negative Metastatic Breast Cancer SAN ANTONIO--(BUSINESS WIRE)--Dec. 10, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate (ADC) in development for patients with LIV-1-expressing metastatic breast can... 
Printer Friendly Version
12/07/15Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
-Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate- -Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Demonstrate a Three-Year Overall Survival Rate of 80 Percent, with Estimated Median Progression-Free Survival... 
Printer Friendly Version
12/07/15Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015
-Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy- -Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL- -ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials- ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 7, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted sever... 
Printer Friendly Version
12/07/15Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015
-33A Combination Therapy and Monotherapy Demonstrate Encouraging Anti-leukemic Activity in AML; Data Highlighted in Oral Presentations- -Planning 33A Phase 3 Trial in Older AML Patients- ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 7, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, De... 
Printer Friendly Version
12/06/15Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015
-Updated Data from Phase 1 Clinical Trials Support Further Clinical Evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL- -First Preclinical Data Presented for SGN-CD19B, a Novel Antibody-Drug Conjugate with PBD Dimer Payload; Phase 1 Clinical Trial in B-cell Malignancies to Begin in 2016- ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 6, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN)... 
Printer Friendly Version
12/02/15Seattle Genetics to Present at Oppenheimer Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 2, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 26th Annual Oppenheimer Healthcare Conference on Wednesday, December 9, at 8:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattl... 
Printer Friendly Version
12/01/15Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 1, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 7, 2015 during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, FL. Members of Seattle Genetics’ management team and an industry expert will discuss data being presented at the conference from multiple programs, most notably ADCETRIS® (brentuximab ... 
Printer Friendly Version
11/23/15Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia
-Trial Based on Anti-Leukemic Activity Observed in Ongoing Phase 1 Clinical Trials Evaluating SGN-CD33A in AML- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 23, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1/2 clinical trial of SGN-CD33A (vadastuximab talirine) in patients with relapsed or refractory acute myeloid leukemia (AML). The trial will evaluate SGN-CD33A monotherapy as a pre-conditioning regimen prior to... 
Printer Friendly Version
11/05/15Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs
-ADCETRIS Data Featured in 17 Presentations, Including Eight Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Expressing Malignancies- -Clinical Data for SGN-CD33A (Vadastuximab Talirine) and SGN-CD19A (Denintuzumab Mafodotin) ADC Programs to be Highlighted in Oral Presentations- -First Disclosure of Two Novel PBD-Based ADCs with Planned Clinical Trial Initiations in 2016- BOTH... 
Printer Friendly Version
10/29/15Seattle Genetics Reports Third Quarter 2015 Financial Results
-Total Third Quarter 2015 Revenues of $84.1 Million, Including Record $59.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -ADCETRIS 2015 U.S. and Canada Net Sales Guidance Increased to a Range of $218 Million to $223 Million- -More than Twenty Presentations at ASH Annual Meeting Featuring Data on ADCETRIS, SGN-CD33A and Other Antibody-Drug Conjugate Pipeline Programs- -Conference Call Today at... 
Printer Friendly Version
10/29/15Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-Trial Based on Data From Phase 1 Trial in B-cell Non-Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 29, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the initiation of a randomized phase 2 clinical trial of denintuzumab mafodotin (SGN-CD19A) in combination with the second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse lar... 
Printer Friendly Version
10/28/15Seattle Genetics to Present at Credit Suisse Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 28, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, President and Chief Executive Officer, will present at the Credit Suisse Healthcare Conference on Tuesday, November 10, at 12:30 p.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About S... 
Printer Friendly Version
10/27/15Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
-ECHELON-1 Data Anticipated in 2017 to 2018 Timeframe- BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the companies have achieved completion of target patient enrollment in the phase 3 ECHELON-1 clinical trial. ECHELON-1 is a randomized trial evaluating ADCETRIS (brentuximab vedotin) as part of a front... 
Printer Friendly Version
10/19/15Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Trial Based on Encouraging Data in CD30-Expressing Relapsed/Refractory DLBCL, the Most Common Type of Aggressive Non-Hodgkin Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 19, 2015-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced the initiation of a randomized phase 2 clinical trial of Rituxan (rituximab) and bendamustine with or without ADCETRIS (brentuximab vedotin) in relapsed or refractory patients with CD30-expressing diffus... 
Printer Friendly Version
10/08/15Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2015 Financial Results on October 29, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 8, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its third quarter 2015 financial results on Thursday, October 29, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Th... 
Printer Friendly Version
10/07/15Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma
-First of Two Planned Trials Combining ADCETRIS and Opdivo Under Clinical Collaboration Agreement with Bristol-Myers Squibb- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 7, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of frontline treatment... 
Printer Friendly Version
09/14/15Seattle Genetics Announces Exercise of Over-Allotment Option
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 14, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the underwriters of its previously announced public offering of common stock have exercised in full their over-allotment option to purchase an additional 1,756,097 shares of common stock. Including this option exercise, total gross proceeds from the offering of an aggregate of 13,463,415 shares at a price to the public of $41.00 per share will be ... 
Printer Friendly Version
09/10/15Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 10, 2015-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced the pricing of an underwritten public offering of 11,707,318 shares of its common stock at a price to the public of $41.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be ... 
Printer Friendly Version
09/09/15Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 9, 2015-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock. All of the shares are being offered by Seattle Genetics. In addition, Seattle Genetics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 of shares of its common stock at the public offerin... 
Printer Friendly Version
09/09/15Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)
-Results from Two Investigator-Sponsored Phase 2 Clinical Trials Recently Published in the Journal of Clinical Oncology Evaluating ADCETRIS in Patients with Relapsed CTCL Demonstrate 70 Percent or Greater Objective Response Rate- -ALCANZA Data Anticipated in Second Half of 2016- BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 9, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the company and its collaborator, Takeda Pharm... 
Printer Friendly Version
08/17/15Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation
-FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results- -AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who Fail Autologous Hematopoietic Transplantation or who Fail at Least Two Prior Multi-Agent Chemotherapy Regimens and are Not Autologous Hematopoietic Transplantation Candidates- -Label Expansion Represents Third Indication for ADCETRIS in the U.... 
Printer Friendly Version
07/30/15Seattle Genetics Reports Second Quarter 2015 Financial Results
-Total Second Quarter 2015 Revenues of $77.1 Million, Including Record $55.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -ADCETRIS 2015 Net Sales Guidance Increased to a Range of $210 Million to $220 Million- -Potential ADCETRIS Label Expansion through AETHERA Supplemental Biologics License Application (BLA) Currently Under FDA Priority Review; PDUFA Action Date August 18, 2015- -Additional ... 
Printer Friendly Version
07/09/15Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 9, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus). Lupus is a chronic autoimmune disease in which the body’s own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death. ADCETRIS is an antibody-drug conjugate (... 
Printer Friendly Version
07/08/15Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial Results on July 30, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 8, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2015 financial results on Thursday, July 30 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thurs... 
Printer Friendly Version
06/17/15Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
-Additional Analysis of Phase 3 AETHERA Data Demonstrates ADCETRIS Consolidation Therapy Significantly Extends Progression-Free Survival in Primary-Refractory Hodgkin Lymphoma Patients- BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 17, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced several ADCETRIS (brentuximab vedotin) data presentations at the 13th International Conference on Malignant Lymphoma (ICML) being held June 17 to 19, 20... 
Printer Friendly Version
06/08/15Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration
-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the Development of Next Generation Cellular Immunotherapy Agents that Combine Unum’s Universal T-cell Approach with Select Seattle Genetics Targets and Antibodies- BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2015-- Seattle ... 
Printer Friendly Version
06/01/15Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting
CHICAGO--(BUSINESS WIRE)--Jun. 1, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 29 to June 2, 2015, in Chicago, IL. ADCETRIS is an antibody-drug conjugate (A... 
Printer Friendly Version
05/28/15Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May 28, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL. Presentations will feature data from several corporate and investigator-sponsored trials w... 
Printer Friendly Version
04/30/15Seattle Genetics Reports First Quarter 2015 Financial Results
-Total First Quarter 2015 Revenues of $82.2 Million, Including $48.9 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Supplemental Biologics License Application (BLA) Filed by FDA with Priority Review for Phase 3 AETHERA Trial; PDUFA Date August 18, 2015- -Completed Special Protocol Assessment (SPA) Amendments for ECHELON-1 and ECHELON-2 Phase 3 Confirmatory Trials- -Conference Call Today at 4:30 p.m. ... 
Printer Friendly Version
04/28/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 28, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. 40th Annual Deutsche Bank Health Care Conference Wednesday, May 6, 9:20 a.m. Eastern Time, Boston ... 
Printer Friendly Version
04/20/15FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse
-PDUFA Action Date August 18, 2015- -Submission of Supplemental BLA Based on Positive Phase 3 AETHERA Clinical Trial Results Recently Published in The Lancet- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 20, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETH... 
Printer Friendly Version
04/16/15Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR) Annual Meeting
-Multiple Data Presentations Support Antibody-Drug Conjugate (ADC) Program Development Plans and Highlight Technology Advances- -SEA-CD40 Immuno-Oncology Preclinical Data Show Potent Activation of Antigen Presenting Cells- -ADCETRIS® (Brentuximab Vedotin) Shown to Induce Immunogenic Cell Death in Preclinical Studies; Combination Clinical Trials Planned with Nivolumab- -Senior Management to Present in Multiple Sessions on Ce... 
Printer Friendly Version
04/13/15Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 13, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2015 financial results on Thursday, April 30 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thu... 
Printer Friendly Version
02/25/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 35th Annual Health Care Conference Tuesday, March 3, 8:40 a.m. Eastern Tim... 
Printer Friendly Version
02/18/15Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse. A... 
Printer Friendly Version
02/17/15Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors
-SEA-CD40 Utilizes Sugar-Engineered Antibody Technology Designed to Target CD40 and Stimulate the Immune System- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 17, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SEA-CD40 for multiple types of advanced solid tumors. SEA-CD40 is a novel investigational immuno-oncology agent targeted to CD40, a widely expressed stimulatory receptor found on ant... 
Printer Friendly Version
02/10/15Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
-Total 2014 Revenues of $286.8 Million, Including $178.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Phase 3 AETHERA Supplemental BLA Submission Planned in First Quarter 2015- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December... 
Printer Friendly Version
02/05/15Seattle Genetics to Present at Leerink Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Leerink Global Healthcare Conference on Thursday, February 12, at 11:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
01/21/15Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 21, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE a... 
Printer Friendly Version
01/12/15Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
BOTHELL, Wash. & NEW YORK--(BUSINESS WIRE)--Jan. 12, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 ... 
Printer Friendly Version
01/06/15Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 11:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version